For the Inventor, By the Inventor

Enter assignee name

Université D'angers

USPTO Granted Patents = 55

% Expired Patents = 43.6

CIPO Patents = 4

EPO Patents = 51

Forward Citations = 39

Loading Chart...

Loading Chart...

145 inventors (with patents filed for the assignee):

Paul Cales (7 out of 7 patents)

Jean-Pierre Benoit (7 out of 19 patents)

Patrick Saulnier (5 out of 6 patents)

4. Yannick Jacques (3 out of 8 patents)

5. Erwan Mortier (3 out of 8 patents)

6. Pascal Richomme (3 out of 4 patents)

7. Jean-Jacques Helesbeux (3 out of 3 patents)

8. Gilles Hunault (3 out of 3 patents)

9. Joël Eyer (3 out of 3 patents)

10. Ariane Plet (2 out of 6 patents)

11. François Guerard (2 out of 3 patents)

12. Jean-François Gestin (2 out of 4 patents)

13. Yong-Sok Lee (2 out of 3 patents)

14. Catherine Guette (2 out of 3 patents)

15. Mario Campone (2 out of 2 patents)

Core Competencies:

Peptide

Cancer Treatment

Microbial Identification

Lipid Nanocapsules

Thrombotic Microangiopathies

Autoimmune Diseases

Fibrosis Tests

Drug Delivery System

Plant Protection

Radiopharmaceuticals

Non-Invasive Diagnostics

Biomarkers

55 patents: Sort by Forward Citations

1. 12617831 - PEPTIDE TARGETING GIP AND GLP-2 RECEPTORS FOR TREATING BONE DISORDERS (2026-05-05),

2. 12405267 - Diagnosis, prognosis and treatment of a disease related to a decrease of (2025-09-02),

3. 12186366 - Clusterin for use in the treatment of thrombotic microangiopathies (2025-01-07),

4. 12181415 - Method for the quick identification of microorganisms by analysis of excitation-emission matrices (2024-12-31),

5. 12144896 - Drug delivery system (2024-11-19),

6. 12120892 - Organic-inorganic hybrid perovskites (2024-10-15),

7. 11723948 - Method for treating and prognosing cancer (2023-08-15),

8. 11605460 - Multi-targeted fibrosis tests (2023-03-14),

9. 11566260 - Potentiating agents for protecting plants from fungal infections (2023-01-31),

10. 11096986 - Use of a neurofilament peptide for targeting neural stem cells (2021-08-24),

11. 11087870 - System and method of traceability of a dental prosthesis, and corresponding dental prosthesis (2021-08-10),

12. 11008374 - Uses of IL-15 antagonists for the treatment of autoimmune and inflammatory diseases (2021-05-18),

13. 10861582 - Non-invasive method for assessing liver fibrosis progression (2020-12-08),

14. 10859577 - Method for in vitro diagnosing and prognosing of triple negative breast cancer recurrence (2020-12-08),

15. 10858452 - Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases (2020-12-08),

Company Overview

Université D'Angers is a prominent academic institution located in Angers, France, specializing in biomedical innovations. The university focuses on advancing research in various critical areas, including peptide development, cancer treatment, and microbial identification. Its research initiatives also encompass lipid nanocapsules, thrombotic microangiopathies, autoimmune diseases, and fibrosis tests, contributing to the evolution of drug delivery systems. The institution plays a vital role in fostering scientific advancements that address significant health challenges.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

55 Patents

#1 in Angers

#439 in France

#12,922 in the World

Université D'angers

Forward Citations = 39

145 inventors:

Paul Cales (7 out of 7 patents)

Jean-Pierre Benoit (7 out of 19 patents)

Patrick Saulnier (5 out of 6 patents)

4. Yannick Jacques (3 out of 8 patents)

5. Erwan Mortier (3 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Université D'angers. Retrieved from https://idiyas.com/company/universite-d-angers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…